Ratios

		vs industry	vs history
P/E(ttm)	13.80	PFE's P/E(ttm) is ranked higher than 75% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 29.76 vs. PFE: 13.80 )	PFE' s 10-Year P/E(ttm) Range Min: 9.46   Max: 209 Current: 13.8 9.46 209
P/B	2.56	PFE's P/B is ranked higher than 58% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 3.00 vs. PFE: 2.56 )	PFE' s 10-Year P/B Range Min: 1.32   Max: 20.43 Current: 2.56 1.32 20.43
P/S	3.73	PFE's P/S is ranked lower than 61% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 2.32 vs. PFE: 3.73 )	PFE' s 10-Year P/S Range Min: 1.72   Max: 10.81 Current: 3.73 1.72 10.81
PFCF	14.13	PFE's PFCF is ranked higher than 80% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 25.89 vs. PFE: 14.13 )	PFE' s 10-Year PFCF Range Min: 5.02   Max: 90.57 Current: 14.13 5.02 90.57
EV-to-EBIT	17.6	PFE's EV-to-EBIT is ranked higher than 94% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 21.70 vs. PFE: 17.6 )	PFE' s 10-Year EV-to-EBIT Range Min: 6.5   Max: 64.3 Current: 17.6 6.5 64.3
PEG	3.14	PFE's PEG is ranked higher than 83% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 1.23 vs. PFE: 3.14 )	PFE' s 10-Year PEG Range Min: 0.88   Max: 202.67 Current: 3.14 0.88 202.67
Shiller P/E	21.22	PFE's Shiller P/E is ranked higher than 94% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 30.12 vs. PFE: 21.22 )	PFE' s 10-Year Shiller P/E Range Min: 8.49   Max: 36.31 Current: 21.22 8.49 36.31

Dividend & Buy Back

		vs industry	vs history
Dividend Yield	3.18	PFE's Dividend Yield is ranked higher than 94% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 1.36 vs. PFE: 3.18 )	PFE' s 10-Year Dividend Yield Range Min: 0.71   Max: 10.4 Current: 3.18 0.71 10.4
Dividend Payout	0.5	PFE's Dividend Payout is ranked higher than 87% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 0.86 vs. PFE: 0.5 )	PFE' s 10-Year Dividend Payout Range Min: 0.36   Max: 1.12 Current: 0.5 0.36 1.12
Dividend growth (3y)	2.4	PFE's Dividend growth (3y) is ranked higher than 90% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: -0.95 vs. PFE: 2.4 )	PFE' s 10-Year Dividend growth (3y) Range Min: -11.2   Max: 16.5 Current: 2.4 -11.2 16.5
Yield on cost (5-Year)	2.20	PFE's Yield on cost (5-Year) is ranked higher than 81% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 1.42 vs. PFE: 2.20 )	PFE' s 10-Year Yield on cost (5-Year) Range Min: 0.49   Max: 7.16 Current: 2.2 0.49 7.16
Share Buyback Rate	-1.6	PFE's Share Buyback Rate is ranked higher than 70% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: -2.00 vs. PFE: -1.6 )	PFE' s 10-Year Share Buyback Rate Range Min: 2.3   Max: -12.6 Current: -1.6

Valuation & Return

		vs industry	vs history
Price/Net Current Asset Value	10.6	PFE's Price/Net Current Asset Value is ranked higher than 70% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 10.20 vs. PFE: 10.6 )	PFE' s 10-Year Price/Net Current Asset Value Range Min: 7.1   Max: 53.5 Current: 10.6 7.1 53.5
Price/DCF (Projected)	1	PFE's Price/DCF (Projected) is ranked higher than 74% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 1.60 vs. PFE: 1 )	PFE' s 10-Year Price/DCF (Projected) Range Min: 0.7   Max: 2.4 Current: 1 0.7 2.4
Price/Median PS Value	1	PFE's Price/Median PS Value is ranked higher than 84% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 0.70 vs. PFE: 1 )	PFE' s 10-Year Price/Median PS Value Range Min: 0.6   Max: 2.7 Current: 1 0.6 2.7
Price/Peter Lynch Fair Value	1.8	PFE's Price/Peter Lynch Fair Value is ranked lower than 65% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 1.60 vs. PFE: 1.8 )	PFE' s 10-Year Price/Peter Lynch Fair Value Range Min: 0.9   Max: 8 Current: 1.8 0.9 8
Earnings Yield (Greenblatt)	5.70	PFE's Earnings Yield (Greenblatt) is ranked lower than 74% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 5.90 vs. PFE: 5.70 )	PFE' s 10-Year Earnings Yield (Greenblatt) Range Min: 1.6   Max: 15.3 Current: 5.7 1.6 15.3
Forward Rate of Return (Yacktman)	11.97	PFE's Forward Rate of Return (Yacktman) is ranked higher than 75% of the 375 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 9.82 vs. PFE: 11.97 )	PFE' s 10-Year Forward Rate of Return (Yacktman) Range Min: 6.3   Max: 18.4 Current: 11.97 6.3 18.4

Business Description

Pfizer Inc. was incorporated under the laws of the State of Delaware on June 2, 1942. It is a research-based global pharmaceutical company applying innovative science to improve world health. It discovers, develops, manufactures and markets prescription medicines for humans and animals. The company operates in two business segments: Biopharmaceutical and Diversified. Biopharmaceutical segment includes the Primary Care, Specialty Care, Established Products, Emerging Markets and Oncology customer-focused units, which include products that prevent and treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye disease and endocrine disorders, among others. Diversified segment includes Animal Health products that prevent and treat diseases in livestock and companion animals; Consumer Healthcare products that include over-the-counter health care products such as pain management therapies, cough/cold/allergy remedies, dietary supplements, hemorrhoidal care and personal care items; Nutrition products such as infant and toddler formula products; and Capsugel, which represents its gelatin capsules business. Biopharmaceutical segment includes products like Lipitor, Norvasc, Caduet, Chantix/Champix, Lyrica, Revati, Geodon/Zeldox, Aricept, Celebrex, Zyvox, Viagra, Detrol/Detrol LA, Sutent, Xalatan, Genotropin, Vfend, Effexor, Prevnar/Prevnar7, Enbrel, Zosyn (Tazocin internationally), Premarin, Hemophilia, Protonix and Spiriva. Diversified segment includes Animal Health unit, in which the Company discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals, and Consumer Healthcare, Nutirition and Capsugel, which is a product line that includes not only hard gelatin capsules, but also liquid, softgel, non-animal, and fish gelatin capsules, all for use in pharmaceutical and dietary supplement dosage delivery. The products are sold around the world under brand-name, logo and certain product design trademarks. Raw materials essential to the company's businesses are purchased worldwide in the ordinary course of business from numerous suppliers. In general, these materials are available from multiple sources. The Company is subject to regulated by national, state and local agencies.
Company Website
SEC Reports

Industry:	Drug Manufacturers - Major
Compare:	GSK, JNJ, RHHBY, NVS, ABT
Traded in other countries:	PFZ.UK, PFEBC.Belgium, PFE.Sweden, PFE.Switzerland, PFE.Germany

» More Articles for PFE

Headlines

Articles On GuruFocus.com

20 Mega Caps and Their Dividend Payments and Which to Consider May 17 2013

3 Dogs of the Dow With Highest Earnings Growth Apr 27 2013

100 Most-Sold Stocks by Famous Investment Gurus Apr 11 2013

20 Best-Yielding Health Care Stocks - Less Volatile Than the Market Apr 02 2013

3 Dogs of the Dow with the Highest Expected Earnings Growth Mar 27 2013

10 Best Dividend Paying Drug Manufacturing Stocks Mar 02 2013

My 3 Favorite Dogs of the Dow Jones Feb 26 2013

Why I Want You to Take an Axe to Your Dividend Stock Portfolio Feb 06 2013

2013: Breakout or Comeuppance? Jan 28 2013

The Best Dogs of the Dow Jones as of December 2012 Dec 26 2012

Personalized Checklist